Trial · NCT04937452
Dopaminergic Therapy for Frontotemporal Dementia Patients
NCT04937452, Phase 2, Completed, I.R.C.C.S. Fondazione Santa Lucia
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Dopaminergic Therapy for Frontotemporal Dementia Patients. Trials, record NCT04937452. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04937452
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dopaminergic Therapy for Frontotemporal Dementia Patients
- NCT number
- NCT04937452
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 75 participants, actual
- Lead sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Conditions
Frontotemporal Dementia, Dementia, Aphasia, Primary Progressive, Pick Disease of the Brain, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurocognitive Disorders, Mental Disorders, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Proteostasis Deficiencies, Metabolic Disease, Aphasia, Speech Disorders, Language Disorders, Communication Disorders, Neurobehavioral Manifestations, Neurologic Manifestations
- Interventions
- Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo
- First posted
- 2021-06-24
- Last updated
- 2024-10-22
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frontal Assessment Battery (FAB) | 24 weeks | Battery to evaluate executive functions. The scores range from 0-18 with a higher score meaning less cognitive impairment. |
| Secondary | Neuropsychiatric Inventory (NPI) scale | 24 weeks | Battery to assess behavioral changes. The scores range from 0-144 with a higher score meaning more severe behavioural disturbances. |
| Secondary | Frontal Behavioural Inventory (FBI) | 24 weeks | Battery to assess behavioral changes. The scores range from 0-72 with a higher score meaning more severe behavioural disturbances. |
| Secondary | Clinical Dementia Rating scale-Frontotemporal dementia Sum Of Boxes (CDR-FTDSOB) | 24 weeks | Battery to evaluate global disease severity. The scores range from 0-24 with a higher score meaning higher disease severity. |
| Secondary | Screening for aphasia in Neurodegeneration (SAND) scale | 24 weeks | Battery to evaluate language functions. The scores range from 0-84 with a higher score meaning less severe language deficits. |
| Secondary | Mini Mental State Examination (MMSE) | 24 weeks | battery to evaluate global cognition. The scores range from 0-30 with a higher score meaning less cognitive impairment. |
| Secondary | Addenbrooke's Cognitive Examination Revised (ACE-R) | 24 weeks | battery to evaluate global cognition. The scores range from 0-100 with a higher score meaning less cognitive impairment. |
| Secondary | Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) | 24 weeks | battery to evaluate activities of daily living. The scores range from 0-78 with lower scores indicating more severe functional impairment. |
| Secondary | CGIC questionnaire | 24 weeks | questionnaire to evaluate clinically meaningful change |
| Secondary | 18F-FDG CT/PET | 24 weeks | Change in brain glucose metabolism will be measured via FDG-PET |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40809903 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04937452
GET https://conductscience.org/api/trials/v1/NCT04937452/registered